HIV-1 reverse transcriptase and hepatitis B virus DNA polymerase (None (the accepted abbreviations are HIV-1 RT for "HIV-1 reverse transcriptase" and HBV polymerase or HBV RT for "hepatitis B virus DNA polymerase," but not for the paired target as named here))

HIV-1 reverse transcriptase is a multifunctional enzyme essential for replication of the human immunodeficiency virus type 1, responsible for converting the viral single-stranded RNA genome into double-stranded DNA, which is then integrated into the host genome[1][2][9]. The enzyme operates as a heterodimer of p66 and p51 subunits, harboring both DNA polymerase and ribonuclease H (RNase H) activities in the p66 subunit[1][5]. Hepatitis B virus DNA polymerase, sometimes referred to as HBV reverse transcriptase, is essential for hepatitis B virus replication and possesses polymerase, RNase H, and unique terminal protein (TP) and spacer domains required for protein priming of viral DNA synthesis[6][8]. Both enzymes are central targets for antiviral therapy, though drug resistance remains a significant clinical challenge. While they share some structural and mechanistic similarities, especially in their polymerase and RNase H functions, they are distinct viral proteins encoded by different viruses and should be enumerated as separate therapeutic targets.

Other names

HIV-1 RT (for HIV-1 reverse transcriptase)HBV RT (for HBV polymerase)HBV polymeraseReverse transcriptase (generic)RT (abbreviation when context is clear)

Nucleos(t)ide reverse transcriptase inhibitors (NRTIs): compete with natural nucleotides and cause chain termination during DNA synthesis Non-nucleoside reverse transcriptase inhibitors (NNRTIs): bind to allosteric sites on HIV-1 RT, inhibiting enzyme activity Dual or domain-specific inhibition (some experimental compounds target both polymerase and RNase H domains)